International, Multicenter Randomized Preclinical Trials in Translational Stroke Research: It's Time to Act

Translational stroke research is in a crisis, and pharmaceutical companies continue to exit the field. Many reasons for the apparently insurmountable barrier between the bench and bedside in stroke drug development have been identified. It is time to act now to bridge the gap between preclinical and clinical studies of purported new therapies. We strongly believe that it is too early to abandon translational stroke research.